Pharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist
F. Awouters, C. J. E. Niemegeers, Anton A. H. P. Megens, Theo Meert, Paul A. J. Janssen
Drug Development Research 1988 DOI: 10.1002/ddr.430150107 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pharmacological study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Ritanserin |
| Dose | 0.0070 to 40 mg/kg |
| Topics | Serotonin |
| Keywords | Ritanserin Tryptamine Antagonism Antagonist Pharmacology Histamine Endocrinology Methysergide 5-HT Receptor |
| Citations | 139 |
| Key points | Ritanserin is a very effective, relatively long-acting, and specific central serotonin S2 antagonist in rats. |
Abstract
Abstract Ritanserin, a novel methylenepiperidine derivative, was studied in a wide range of common pharmacological tests mainly in rats. The lowest ED 50 , 0.0070 mg/kg, was obtained against tryptamine‐induced cyanosis. At 0.037 mg/kg, tryptamine‐induced bilateral clonic seizures were inhibited. Slightly higher doses, up to 0.11 mg/kg, inhibited mescaline and 5‐hydroxytryptophan (5‐HTP)‐induced head twitches and antagonized tryptamine‐induced coarse body tremors. Ritanserin did not generalize with LSD but was a weak antagonist of the LSD‐discriminative stimulus. Potent serotonin S 2 ‐antagonism was confirmed by the inhibition of reactions mediated by endogenous serotonin, such as reversal of mast cell serotonin (5‐HT) cyanosis (0.012 mg/kg) and inhibition of gastric lesions (0.028 mg/kg). The lowest dose reducing the intensity of serotonin‐induced skin reactions was 0.04 mg/kg. Reduction of histamine‐induced skin reactions required a dose of at least 10 mg/kg. Time‐course studies in several tests indicated a relatively long duration of serotonin S 2 ‐antagonism. Ritanserin doses up to 40 mg/kg were devoid of central dopamine antagonism and did not interfere with the neurotransmitters norepinephrine and acetylcholine. In an additional series of interactions and functional tests, ritanserin was virtually devoid of effect. In the wide range of tests, peripheral histamine antagonism was the first activity component unrelated to serotonin and it was observed at 270 times the dose for central S 2 ‐antagonism. It is concluded that ritanserin is a very effective central serotonin S 2 ‐antagonist which is at the same time relatively long acting and very specific.
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |